Original scientific paper

https://doi.org/10.20471/acc.2024.63.02.3

Usporedba testova Avvott Real Time Sars-CoV-2 i Liferiver Novel Coronavirus Real Time Multiplex za RT-PCR detekciju SARS-CoV-2 iz nazofaringealnih briseva

Jelena Stojčević-Maletić orcid.org/0000-0002-9962-0810 ; University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia; University Clinical Center of Vojvodina, Center for Laboratory Diagnostics, Novi Sad, Serbia *
Iva Barjaktarović ; University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia; University Clinical Center of Vojvodina, Center for Laboratory Diagnostics, Novi Sad, Serbia
Mirjana Đerić ; University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia; University Clinical Center of Vojvodina, Center for Laboratory Diagnostics, Novi Sad, Serbia
Velibor Čabarkapa ; University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia; University Clinical Center of Vojvodina, Center for Laboratory Diagnostics, Novi Sad, Serbia
Vladimir Petrović ; University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia; Institute of Public Health of Vojvodina, Novi Sad, Serbia
Aleksandra Patić ; University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia; Institute of Public Health of Vojvodina, Novi Sad, Serbia
Slobodanka Bogdanović-Vasić ; Šabac High School of Medical and Business-Technology School of Professional Studies, Šabac, Serbia

* Corresponding author.

Abstract

Cilj ove studije bio je usporediti učinkovitost dvaju odobrenih testova, Abbott Real Time SARS-CoV-2 (ACOV) testa
(Abbott Molecular Inc., North Chicago, IL, SAD) i Liferiver Novel Coronavirus Real Time Multiplex RT-PCR (Liferiver
2019-nCoV) testa (BioVendor Group, Brno, Češka Republika) i utvrditi utječe li odabir ciljanih gena na specifičnost testa.
Uključili smo 105 nazofaringealnih briseva odraslih osoba sa simptomima ili sumnjom na koronavirusnu bolest 2019
(COVID-19) u dobi od 26 do 91 godine, koji su prvobitno testirani primjenom testa ACOV, a potom testa Liferiver 2019-
nCoV. U ovoj usporednoj analizi otkrili smo da je test ACOV otkrio više slučajeva infekcije COVID-19 od testa Liferiver
2019-nCoV. Liferiver 2019-nCoV test pokazao je visoku razinu slaganja s testom ACOV. Pozitivni postotak slaganja bio je
88,89% (95% interval pouzdanosti (95% CI): 77,42%-100,0%) i Cohenov kappa koeficijent 0,901 (95% CI: 0,817-0,985).
Negativni postotak slaganja bio je 94,12% (95% CI: 89,74%-98,50%), dok je 4,76% SARS-CoV-2 slučajeva bilo lažno
negativno pomoću Liferiver testa. Međutim, zbog mogućih lažno negativnih rezultata pomoću testa Liferiver 2019-nCOV
preporučamo kompletno testiranje testom ACOV.

Keywords

Molekularna dijagnostika; PCR; Izolacija RNK; Otkrivanje virusa

Hrčak ID:

327944

URI

https://hrcak.srce.hr/327944

Publication date:

31.10.2025.

Article data in other languages: english

Visits: 1.031 *